Bank of New York Mellon Corp Has $436,000 Stake in Sientra, Inc. (NASDAQ:SIEN)

Bank of New York Mellon Corp increased its stake in shares of Sientra, Inc. (NASDAQ:SIEN) by 0.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 51,760 shares of the medical instruments supplier’s stock after buying an additional 250 shares during the period. Bank of New York Mellon Corp owned about 0.27% of Sientra worth $436,000 as of its most recent SEC filing.

Receive News & Ratings for Sientra Inc. Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Separately, Wells Fargo & Company MN boosted its stake in shares of Sientra by 0.3% in the first quarter. Wells Fargo & Company MN now owns 12,871 shares of the medical instruments supplier’s stock valued at $108,000 after buying an additional 40 shares during the period. Hedge funds and other institutional investors own 78.57% of the company’s stock.

Shares of Sientra, Inc. (NASDAQ:SIEN) traded up 1.14% on Wednesday, reaching $10.63. 26,221 shares of the company’s stock traded hands. The firm’s market cap is $203.37 million. The company’s 50-day moving average price is $10.51 and its 200 day moving average price is $8.99. Sientra, Inc. has a one year low of $6.92 and a one year high of $11.47.

Sientra (NASDAQ:SIEN) last posted its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported ($0.55) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.04. The firm had revenue of $8.20 million for the quarter, compared to analysts’ expectations of $6.97 million. Sientra had a negative net margin of 173.83% and a negative return on equity of 52.30%. The company’s revenue for the quarter was up 32.3% on a year-over-year basis. On average, equities analysts forecast that Sientra, Inc. will post ($2.90) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was first reported by [[site]] and is the sole property of of [[site]]. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at [[permalink]].

SIEN has been the subject of several research analyst reports. Lake Street Capital restated a “buy” rating and set a $15.00 price objective (up from $11.00) on shares of Sientra in a research report on Wednesday, August 2nd. Stephens initiated coverage on shares of Sientra in a research report on Tuesday, July 11th. They set an “overweight” rating and a $12.00 price objective for the company. Zacks Investment Research downgraded shares of Sientra from a “hold” rating to a “sell” rating in a research report on Wednesday, May 17th. Finally, ValuEngine upgraded shares of Sientra from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd.

About Sientra

Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.